1.335
전일 마감가:
$1.34
열려 있는:
$1.38
하루 거래량:
31,701
Relative Volume:
0.25
시가총액:
$505.35M
수익:
-
순이익/손실:
$-33.08M
주가수익비율:
-0.4541
EPS:
-2.94
순현금흐름:
$-25.68M
1주 성능:
-2.55%
1개월 성능:
-5.99%
6개월 성능:
-20.06%
1년 성능:
+7.66%
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
명칭
Chemomab Therapeutics Ltd Adr
전화
972-77-331-0156
주소
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
CMMB을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CMMB
Chemomab Therapeutics Ltd Adr
|
1.34 | 26.41M | 0 | -33.08M | -25.68M | -2.94 |
![]()
ONC
Beone Medicines Ltd Adr
|
258.50 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
449.85 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.39 | 40.54M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
84.64 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
491.24 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-05-13 | 개시 | Maxim Group | Buy |
2024-05-06 | 업그레이드 | Oppenheimer | Perform → Outperform |
2023-12-19 | 재개 | ROTH MKM | Buy |
Chemomab Therapeutics Ltd Adr 주식(CMMB)의 최신 뉴스
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study - sharewise
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Yahoo Finance
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - sharewise
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
RCKT Stock Tanks on Patient Death in Danon Disease Study - Yahoo Finance
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Yahoo Finance
Chemomab prepares for annual shareholder meeting By Investing.com - Investing.com India
Chemomab prepares for annual shareholder meeting - Investing.com
Chemomab Leadership Changes Signal Strategic Momentum Following Positive Clinical Results - Barchart.com
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com
Microsoft Stock After Xbox Price Hike: Buy Or Hold? - Barchart.com
Should You Buy, Sell, Or Hold Nio Stock Amid Firefly Brand Launch? - Barchart.com
UBS Group Q1 Earnings & Revenues Dip Y/Y, Credit Loss Expenses Slip - Barchart.com
This ‘Strong Buy’ Robotaxi Stock Just Got A Huge Bump. Should You Buy Shares Now? - Barchart.com
Chemomab reports promising PSC treatment data - Investing.com
Chemomab Announces New Medical And Clinical Appointments - Barchart.com
Should You Buy Tesla Stock On The ‘Liberation Day’ Dip? - Barchart.com
Should You Dump Tesla Stock As Deliveries Plunge In Q1 And Tariff Fears Escalate? - Barchart.com
The Aurora Cannabis Inc (NASDAQ: ACB) Stock Price: Is It Overvalued? - Stocks Register
How Stable And Growing Is Globavend Holdings Ltd (NASDAQ: GVH)? - Stocks Register
Before Buying AYRO Inc (NASDAQ: AYRO) Stock, Read This First - Stocks Register
Is Advance Auto Parts Inc (NYSE: AAP) A Good Investment For New Investors Now? - stocksregister.com
Nu Holdings Ltd (NYSE: NU) Has Great Upside Potential - stocksregister.com
ZEEKR Intelligent Technology Holding Ltd. ADR (NYSE: ZK): Getting A Free Pass? - stocksregister.com
AT&T, Inc (NYSE: T) Jumps 1.59%: What Could Be On The Way Going Forward? - Stocks Register
Adma Biologics Inc (NASDAQ: ADMA): Blank Check For Growth? - Stocks Register
A Bullish 2025 Outlook For Blink Charging Co (NASDAQ: BLNK) Shares - Stocks Register
In 2025, Linkers Industries Ltd (NASDAQ: LNKS) Shares Will Likely Be Bullish - Stocks Register
Carrier Global Corp (NYSE: CARR): On Track To A Higher Share Price - Stocks Register
Before Buying Avantor Inc (NYSE: AVTR) Stock, Read This First - stocksregister.com
Ally Financial Inc (NYSE: ALLY): An Enticing Stock To Watch - stocksregister.com
Nebokitug shows promise in PSC treatment trial - Investing.com
Q3 Rundown: Sea (NYSE:SE) Vs Other Online Marketplace Stocks - Barchart.com
Does DLocal Limited (NASDAQ: DLO) Still Need To Convince Analysts? - stocksregister.com
Think You Need A Good Stock? Look At This Scilex Holding Company (NASDAQ: SCLX) Analysis - stocksregister.com
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA)’s Stock Boosts 3.25%, But It May Be A Worthy Investment - stocksregister.com
Is WeRide Stock A Buy, Sell, Or Hold As Nvidia Reveals Its $25 Million Bet? - Barchart.com
Chemomab Therapeutics (CMMB) Stock Price, News & Analysis - MarketBeat
How analysts predict Chemomab Therapeutics Ltd ADR (CMMB) will perform this quarter? - US Post News
Nebokitug positioned as potential first FDA-approved PSC treatment By Investing.com - Investing.com South Africa
Arm Just Nabbed A Major Chip Deal With Meta. Is ARM Stock A Buy, Sell, Or Hold Now? - Barchart.com
Nvidia Sends Chinese Self-Driving Stock Up 100%, While Soundhound AI Sells Off - Barchart.com
Up 175% In 2024, Can This Growth Stock Keep Climbing? - Barchart.com
3 Stocks To Benefit From China’s Rare Earth Export Ban On U.S. - Barchart.com
LogicMark Inc (LGMK) Recovers 0.71% From Low: Are We There Yet? - Stocks Register
Is Toyota Stock A Buy, Sell, Or Hold On New Return On Equity Plans? - Barchart.com
3 Pharma Stocks To Buy As California Sounds The Alarm On Bird Flu Cases - Barchart.com
What's Going On With Alibaba Stock? - Barchart.com
Up 47% Post-Election, Can Tesla Stock Keep Soaring? - Barchart.com
Under Trump, European Defense Stocks Will Soar. Here's How To Invest. - Barchart.com
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Investing.com
Chemomab Therapeutics Ltd Adr (CMMB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):